Korean Drug Co. Ltd (014570) — Cash Flow Quality Index

Latest as of September 2025: 1.95x

Korean Drug Co. Ltd (014570) has a Cash Flow Quality Index of 1.95x as of September 2025. Operating cash flow of ₩3.72 Billion exceeds net income of ₩1.91 Billion, indicating high earnings quality where cash backs reported profits. Explore Korean Drug Co. Ltd (014570) long-term investment share to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

1.95x
Operating CF / Net Income

Operating Cash Flow

₩3.72 Billion
KRW

Net Income

₩1.91 Billion
KRW

Data as of

Sep 2025
Most recent filing

Korean Drug Co. Ltd Cash Flow Quality Index (2014–2024)

Historical Cash Flow Quality Index for Korean Drug Co. Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of Korean Drug Co. Ltd to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Korean Drug Co. Ltd (2014–2024)

Year-by-year earnings quality comparison for Korean Drug Co. Ltd. For live market cap and the full company financial profile, see 014570 market cap overview.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2024 1.63x ₩4.87 Billion ₩3.00 Billion ▲ +224.7%
2022 0.50x ₩5.91 Billion ₩11.81 Billion ▼ -48.6%
2021 0.97x ₩8.81 Billion ₩9.04 Billion ▼ -41.9%
2020 1.68x ₩12.33 Billion ₩7.36 Billion ▲ +5.1%
2019 1.59x ₩6.21 Billion ₩3.90 Billion ▲ +80.7%
2018 0.88x ₩5.79 Billion ₩6.56 Billion ▲ +823.6%
2017 0.10x ₩447.20 Million ₩4.68 Billion ▼ -87.8%
2016 0.78x ₩3.96 Billion ₩5.05 Billion ▼ -77.3%
2015 3.46x ₩6.13 Billion ₩1.77 Billion ▲ +66.7%
2014 2.07x ₩4.46 Billion ₩2.15 Billion
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.